Effect of radiofrequency ablation combined with sorafenib on liver function in patients with advanced hepatic carcinoma

Objective To investigate the clinical effect of radiofrequency ablation combined with sorafenib in the treatment of advanced hepatic carcinoma. Methods Total 46 patients with advanced primary liver cancer who were treated in our hospital from February, 2013 to November, 2015 were selected and randomly divided into control group (n=23) and observation group (n=23). The control group was treated with radiofrequency ablation alone, and the observation group was treated with sorafenib on the basis of the control group. The total effective rate, the changes of liver function indexes before and after treatment, and the survival rate of the 1 and 2 years after treatment were observed between the two groups. Results The total effective rate of the observation group was 91.30%, which was significantly higher than that of the control group (65.22%), P<0.05. No significant liver function index before treatment between the two groups (P>0.05), the two groups after treatment of Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and total bilirubin (TBiL) were increased, but the observation group after treatment. The above index level is lower than the control group (P<0.05). The observation group after treatment for 1 years and 2 years survival rates were 86.96%, 78.26%, the control group after treatment for 1 years and 2 years survival rates were 60.87% and 47.83%. The observation group was significantly higher than the control group (P<0.05). Conclusion Radiofrequency ablation combined with sorafenib in the treatment of advanced liver cancer, can obtain accurate curative effect, long-term survival rate is higher, and can reduce liver function damage, has higher clinical application value.